Suyue Wang joins ImmusanT with almost 20 years of diverse experience in research, drug discovery and assay development across a wide spectrum of therapeutic areas for small molecule, peptide and biological drug candidates. Prior to Joining ImmusanT, Dr. Wang was Director of Biology at XRpro Sciences, Inc. (now Icagen, Inc.), where she led the development of label-free assay platforms for ion channels and transporters using XRpro®X-ray fluorescence technology. Prior to that, Dr. Wang led and developed multiple biochemical and cell-based assay platforms supporting peptide inhibitor preclinical projects for oncology, inflammation, and complement disorders at Ra Pharmaceuticals. Earlier in her career, Dr. Wang spent 13 years at Wyeth (which later became Pfizer), where she moved from Staff Scientist to Principal Scientist and served as a project leader for multidisciplinary teams in the fields of cardiovascular and metabolic diseases. Dr. Wang and her group were responsible for target identification, HTS assay development, lead characterization, and mechanism of action and biomarker evaluation of targeting enzymes, GPCRs and nuclear receptors to support numerous preclinical and clinical stage projects.
Suyue received her B.S. in microbiology from Fudan University in China and her Ph.D. in biochemistry from the Department of Biology at North Texas State University, where she studied tRNA and other repetitive DNA elements. She completed her postdoctoral training in Dr. Junying Yuan’s lab at Harvard Medical School, Department of Cell Biology, where she studied the role of caspase signaling in the regulation of inflammation and apoptosis.